San Marcos, CA, United States of America

Achim Hans-Peter Krauss




Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 35(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Achim Hans-Peter Krauss: Pioneering Advances in Ocular Treatments

Introduction

Achim Hans-Peter Krauss is a prominent inventor based in San Marcos, California. With a remarkable portfolio of two patents, he has significantly contributed to the field of pharmacology, particularly in treatments for eye conditions such as glaucoma and ocular hypertension.

Latest Patents

Krauss's latest patents showcase groundbreaking advancements in the pharmacological space. His first patent describes nitric oxide donating prostamides, specifically nitroderivatives of prostaglandins that demonstrate improved pharmacological activity and enhanced tolerability. This innovation offers promising avenues for treating glaucoma and ocular hypertension. Additionally, he has developed a patent for prostaglandin derivatives, which are nitroderivatives of prostaglandin amides that further enhance pharmacological efficacy and patient tolerability for the same eye conditions.

Career Highlights

Achim Krauss holds a key position within Nicox S.A., a company dedicated to developing innovative therapeutics in the field of ophthalmology. His work is characterized by a commitment to advancing health solutions that cater to patients suffering from serious ocular diseases.

Collaborations

Throughout his career, Krauss has collaborated with fellow professionals in the industry, including Francesca Benedini and Valerio Chiroli. These collaborations enable a multidisciplinary approach to research and development, bolstering the innovation pipeline at Nicox.

Conclusion

Achim Hans-Peter Krauss exemplifies innovation in medicine, particularly in treatments for eye diseases. His patented inventions are a testament to his dedication to improving patient outcomes. As the landscape of ocular therapeutics evolves, his contributions will undoubtedly play a vital role in shaping future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…